

**Supporting Information Figure 1**, IL-33 protein in culture medium and caspase-3 activity in SAA-activated monocytes. (A) THP-1 cells were stimulated with 0.05  $\mu$ M SAA for the indicated times. IL-33 in the culture medium was measured by ELISA. The results are representative of three independent experiments. (B) THP-1 cells were stimulated with 0.05  $\mu$ M SAA for the indicated times. Caspase-3 protein activity was detected by Western blotting with a specific anticaspase-3 antibody. Data are representative of three samples pooled from three independent experiments and densitometry values (means + SEM) are shown (B).



**Supporting Information Figure 2**, Effect of FPR2 agonist and antagonist on SAA-induced IL-33 expression. (A) THP-1 cells were stimulated for 8 h with WKYMVm (W-pep, 500 nM), together with different concentrations of SAA (1 nM to 50 nM). Relative changes in IL-33 mRNA were detected by quantitative real-time PCR. (B) WRW4 at indicated concentrations was applied to THP-1 cells 1 h before SAA (0.05  $\mu$ M) stimulation for 8 h. Data shown are means + SEM of six samples pooled from three independent stimulation experiments. \**p* < 0.05, \*\**p* < 0.01, one-way ANOVA followed by Bonderroni post-testing. (C) THP-1 cells were pretreated with or without WRW4 at the indicated concentrations for 1 h and then stimulated with 0.1  $\mu$ M SAA and W-pep (0.1  $\mu$ M), respectively. The changes in intracellular calcium were analyzed. Data were acquired by SoftMax Pro 6 (Molecular Devices) and a typical set of calcium traces from one representative experiment (total of 3) is shown.

| Α  |  |  |  |                              |
|--|--|--|--|------------------------------|
|  |  | IRF7 #1  | IRF7 #2  |                              |
| WT probe:<br>Mut.A probe:<br>Mut.B probe:<br>Mut.AB probe:     | -277 AACAGAA<br>-277 AACA <u>TGC</u><br>-277 AACA <u>TGC</u><br>-277 AACA <u>TGC</u> | ATTTCAAAATGGACAGTGCT<br><u>CG</u> TTCAAAATGGACAGTGCT<br>ATTTCAAAATGGACAGTGCT<br><u>CG</u> TTCAAAATGGACAGTGCT | GGAAGTTGAAGTTTAGGA<br>GGAAGTTGAAGTTTAGGA<br>' <u>TCGA</u> TTGAAGTTTAGGA<br>' <u>TCGA</u> TTGAAGTTTAGGA | -235<br>-235<br>-235<br>-235 |
| B<br>Lane $1 \ 2 \ 3 \ 4 \ 5 \ 6 \ 7$<br>Binding $\rightarrow$ |  |  |  |                              |

**Supporting Information Figure 3**, IRF7 binding to IRF7 #1 site in IL-33 promoter in vitro. (A) Probe sequence and the mutations introduced. WT probe, -277/-235 region of IL-33 promoter with both IRF7 #1 and IRF7 #2 binding sites; Mut.A probe, mutations in IRF7 #1 sites (underlined); Mut.B probe, mutations in IRF7 #2 (underlined); Mut.AB probe, mutations in both IRF7 #1 and IRF7 #2 binding sites (underlined). (B) EMSA with WT or mutant probes of the human IL-33 promoter was performed on HEK-293T cell nuclear protein extracts after overexpression of HAtagged IRF7. Approximately 50 fmol probe were used in Lane 1-6 except for Lane 5 (100 fmol). PF, protein free; CP, cold competitor probe. Data are representative of three experiments.

|                              |   | Devenes Drimer                         |  |
|------------------------------|---|--|--|
| Primer Name                  | Forward Primer<br>(5'-3')                       | Keverse Primer<br>(5'-3')              |  |
| IL-33 pro (-<br>1050 to +49) | AGTTGAGCTCCCCAAGCCTGGTCA<br>GCCA                | GCGACTCGAGTTTCTTCCCTGAAGA<br>GCT       |  |
| IL-33 pro (-662<br>to +49    | GCGAGAGCTCATTACTTCATCCCTTT<br>AT                | GCGACTCGAGTTTCTTCCCTGAAGA<br>GCT       |  |
| IL-33 pro (-520<br>to +49    | ATTAGAGCTCATCTTCTGCGAGATT                       | GCGACTCGAGTTTCTTCCCTGAAGA<br>GCT       |  |
| IL-33 pro (-460<br>to +49    | ATATGAGCTCCCCGTCAGATATGTT                       | GCGACTCGAGTTTCTTCCCTGAAGA<br>GCT       |  |
| IL-33 pro (-300<br>to +49    | TATTGAGCTCGCCAAAAGTGAATAT                       | GCGACTCGAGTTTCTTCCCTGAAGA<br>GCT       |  |
| IL-33 pro (-160<br>to +49    | ATTAGAGCTCCAGATGGAGGGAGG<br>ACGC                | GCGACTCGAGTTTCTTCCCTGAAGA<br>GCT       |  |
| Human IRF7<br>(FL)           | ATAGGATCCATGGCCTTGGCTCCTG<br>AG                 | TATCTCGAGCTAGGCGGGCTGCTC<br>CAG        |  |
| IL-33-pro Mut.<br>A          | ATATAAATGGCAACA <u>TGCG</u> TTCAAAA<br>TGGACAGT | ACTGTCCATTTTGAACGCATGTTGC<br>CATTTATAT |  |
| IL-33-pro Mut.<br>B          | AAAATGGACAGTGCT <u>TCGA</u> TTGAAG<br>TTTAGGAGT | ACTCCTAAACTTCAATCGAAGCACT<br>GTCCATTTT |  |
| Human IL-33                  | TGAATCAGGTGACGGTGTT                             | TGGTCTGGCAGTGGTTTT                     |  |
| Human IRF7                   | AGCCGTACCTGTCACCCTCC                            | CGCAGCAGTTCCTCCGTGT                    |  |
| Human GAPDH                  | TCAAGAAGGTGGTGAAGCA                             | AAGGTGGAGGAGTGGGT                      |  |
| Mouse IL-33                  | TTCTTCGTCCTTCACA                                | CATCTTTCTCCTCCACT                      |  |
| Mouse GAPDH                  | CCTTCCGTGTTCCTACCC                              | CAACCTGGTCCTCAGTGTAG                   |  |
| Chip Primer for<br>RT-PCR    | GGACAGTGCTGAAGTTGAAGTTTA                        | CGTCCTCCCTCCATCTGAATATTT               |  |

Supporting Information Table 1: Primers used for plasmid construction and RT-PCR.